Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (March 2019)
14 slides from Harrow's investor presentation, Mar 18, 2019
Slide 1: Harrow, March 2019
HARROW NASDAQ: HROW MARCH 2019
Slide 2: Safe Harbor
HARROW SAFE HARBOR This presentation contains express “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying
Slide 3: Harrow Health Introduction
Harrow Health Introduction ¢ Mitigate investment risk of drug development for the benefit of shareholders and patients VALUE CREATION + We found pharmaceutical companies + We finance them - We own: * large equity stakes, and * royalties on many of the drug candidates they develop HARROW a>
Slide 4: Harrow Health Introduction
Harrow Health Introduction HARROW HEALTH INC. OH Deconsolidated businesses Royalty opportunities IMprimis p elon Eton's C1100 Py Surface’s SURF-100 PARK Gu rface EES SURF-200, 201 Surface’s SURF-300, 301 MAYFIELD a Melt’s MELT-100** . MEET Mayfield’s MAY-66 8 a Mayfield’s MAY-88 Radley’s RAD-100, 10
Slide 5: Financial Metrics
FINANCIAL METRICS HARROW
Slide 6: Consolidated Financials
Consolidated Financials TRENDS Revenue Growth: SIOOM rev run rate goal in 2021 + 123% revenue CAGR 2014-2018 + Consoliclated revenue grew 55% from 2017-2018 + @3-@4 2018 ophthalmology organic revenue growth of 12% + New ophthalmology product launches expected in 2019 Gross Margins: + Continued expan
Slide 7: Equity Portfolio
Equity Portfolio HARROW’S DECONSOLIDATED EQUITY PORTFOLIO ESTIMATED VALUE: $56M (NON-GAAP)* 7 Melt A $17,500,000 3.5M shares at $5 Eton $27,475,000 3.5M shares at $7.85 3.5M shares at $3.30 “Melt and Surface equity values are estimated and based on the conversion price of Series A preferred stock -
Slide 8: Royalty Rights Portfolio
Royalty Rights Portfolio DRUG PROPOSED MARKET ROYALTY CANDIDATE | INDICATION opportunity | CLINICAL STAGE | “pate INFANTILE SPASMS, $1.1B+ CT-100 RHEUMATIOID “ae PRE-CLINICAL 6% eres (Acthar’ Gel '17 sales) SiSEs EXPECT PHASE II SURF-100 CHRONIC DRY EYE (Restasis"/ Xiidra® 17 DATA IN 2020 4% sales!)
Slide 9: Summary
SUMMARY HARROW
Slide 10: Harrow Health Project
Harrow Health Project 15 Management incentivized to achieve $15 stock price ¢ Pharmaceutical compounding business | Lest is fast growing and cash-flowing * Equity positions in deconsolidated businesses are now valued at ~$56M* (Non-GAAP) ¢ Future stream of royalties in diverse portfolio of drug deve
Slide 11: Appendix and References
APPENDIX AND REFERENCES HARROW
Slide 12: References
References 1. Harrow Health internal business data, including IMS data, 2015-2019, and proprietary surveys, 2015-2019 2. Market Scope, LLC, Comprehensive Report on the Global |OL Market (2013, May). 3. Allen, A. (2007). Vasectomy Risks and Benefits. Retrieved November 08, 2016, from http://www.webmd
Slide 13: Published Clinical Data
Published Clinical Data Kindle, Trevor, MD, et al. (2018, January). Safety and efficacy of intravitreal injection of steroid and antibiotics in the setting of cataract surgery and trabecular microbypass stent. Journal of Cataract and Refractive Surgery. In a study of 483 eyes undergoing cataract sur
Slide 14: Contact details
12264 EL CAMINO REAL, SUITE 350 HARROW | iss (858) 704-4040 H E A LT H ze IR@HARROWINC.COM WWW.HARROWINC.COM